Companies › AbbVie
74 active drug programs in 582 registered trials: 267 Phase 2, 181 Phase 1, 94 Phase 3, 40 Phase 4; Oncology, Other, Immunology, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Venetoclax Apoptosis regulator Bcl-2 inhibitor | BCL2 | Phase 4 | Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia; Myelodysplastic Syndrome (MDS); Chronic Lymphocytic Leukemia … | Nov 2026 |
| OnabotulinumtoxinA Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 4 | Jawline and Neck Appearance; Urinary Bladder, Overactive; Overactive Bladder; Trigeminal Neuralgia … | Jun 2027 |
| Azacitidine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 4 | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) | Jul 2027 |
| Mirvetuximab Soravtansine Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 3 | Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer … | Nov 2026 |
| Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia (CLL) | Nov 2026 |
| Upadacitinib Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | TYK2, JAK3, JAK2, JAK1 | Phase 3 | Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease … | Nov 2026 |
| ABBV-RGX-314 (surabgene lomparvovec, RGX-314) AAV8 vector containing a transgene for anti-VEGF Fab | VEGFA | Phase 3 | AMD; Neovascular Age-related Macular Degeneration; Diabetic Retinopathy (DR); Neovascular Age-Related Macular Degeneration (nAMD) … | Dec 2026 |
| Lutikizumab Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor | IL1A, IL1B | Phase 3 | Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis … | Dec 2026 |
| Navitoclax Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor | BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1 | Phase 3 | Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma … | Dec 2026 |
| Risankizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) … | Jan 2027 |
| ABBV-383 (Etentamig) BCMA-directed bispecific antibody | BCMA | Phase 3 | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; Immunoglobulin Light Chain (AL) Amyloidosis | Feb 2027 |
| Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Depression | Mar 2027 |
| Ubrogepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Migraine; Healthy Volunteer | May 2027 |
| Atogepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Menstrual Migraine (MM); Episodic Migraine; Chronic Migraine | Jul 2027 |
| Elagolix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Endometriosis; Menopause; Infertility | Jul 2027 |
| Telisotuzumab adizutecan Anti-MET antibody-drug conjugate | MET | Phase 3 | Colorectal Cancer; Metastatic Colorectal Cancer; Pancreatobiliary Cancers; Head and Neck Squamous Cell Carcinoma … | Jul 2027 |
| ABBV-706 Delta-like ligand 3 (DLL3) targeted therapy | DLL3 | Phase 3 | Small Cell Lung Cancer; Advanced Solid Tumors | Nov 2027 |
| Telisotuzumab Vedotin (ABBV-399) Tubulin inhibitor; Hepatocyte growth factor receptor binding agent | Tubulin, MET | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer … | Feb 2028 |
| NOA LIFT hyaluronic acid-based dermal filler | – | Phase 3 | Nasolabial Folds | Aug 2028 |
| XEN63 Glaucoma Treatment System Gel stent for intraocular pressure reduction | – | Phase 3 | Primary Open Angle Glaucoma | Nov 2028 |
| NOA VOLUME Crosslinked hyaluronic acid injectable gel | – | Phase 3 | Mid Face Volume Deficit | Jul 2029 |
| ELAPR002f Injectable Gel Space-occupying dermal filler for atrophic acne scars | – | Phase 3 | Acne Scars | Nov 2029 |
| ABBV-1480 | – | Phase 3 | Non-Small Cell Lung Cancer | Dec 2029 |
| Lidocaine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Mid Face Volume Deficit; Blood Gas Analysis; Hemiplegia; Rib Fractures … | – |
| ABBV-701 Undisclosed mechanism (code-named investigational drug) | – | Phase 2 | Crohn's Disease; Healthy Volunteer | Nov 2026 |
| ABBV-932 | – | Phase 2 | Generalized Anxiety Disorder (GAD); Bipolar I or II Disorder; Healthy Volunteer; Bipolar Disorder | Nov 2026 |
| Budigalimab (ABBV-181) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 2 | Hepatocellular Carcinoma; Urothelial Carcinoma; Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Non-Small Cell Lung Cancer … | Nov 2026 |
| Livmoniplimab | – | Phase 2 | Hepatocellular Carcinoma; Urothelial Carcinoma; Non-Small Cell Lung Cancer; Hepatocellular Carcinoma (HCC) … | Nov 2026 |
| ABBV-400 | – | Phase 2 | Unresectable Metastatic Colorectal Cancer; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer | Dec 2026 |
| Emraclidine Muscarinic acetylcholine receptor agonist | – | Phase 2 | Schizophrenia; Healthy Volunteer | Dec 2026 |
| Pivekimab Sunirine Interleukin-3 receptor subunit alpha binding agent | IL3RA | Phase 2 | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm | Dec 2026 |
| ABBV-295 amylin analog | CALCR | Phase 2 | Obesity; Healthy Volunteer | Jan 2027 |
| IMGN151 anti-FOLR1 antibody-drug conjugate | FOLR1 | Phase 2 | Gynecologic Cancers; Endometrial Cancer | Feb 2027 |
| MEDI0618 CALCA receptor antagonist | – | Phase 2 | Migraine | Feb 2027 |
| Ravagalimab CD40 ligand antagonist | CD40LG | Phase 2 | Rheumatoid Arthritis | Feb 2027 |
| Trenibotulinumtoxine (AGN-151586) Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 2 | Forehead Lines; Upper Facial Lines; Glabellar Lines | Feb 2027 |
| Armour Thyroid Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3) | THRA, THRB | Phase 2 | Hypothyroidism | Sep 2027 |
| Icalcaprant | – | Phase 2 | Major Depressive Disorder; Bipolar I Disorder | Sep 2027 |
| AGN-151607-DP | – | Phase 2 | Ventral Hernia; Upper Limb Essential Tremor | Sep 2028 |
| ABBV-142 | – | Phase 2 | Idiopathic Pulmonary Fibrosis | Sep 2029 |
| ABBV-8736 | – | Phase 2 | Crohn's Disease | Jan 2030 |
| Trosunilimab | – | Phase 2 | Crohn's Disease | Jan 2030 |
| Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 1 | Healthy Volunteers | Dec 2026 |
| ABBV-291 | – | Phase 1 | Non-Hodgkin's Lymphoma | Jan 2027 |
| ABBV-744 | – | Phase 1 | Myelofibrosis (MF) | Jan 2027 |
| ABBV-319 B cell depletion | – | Phase 1 | Diffuse Large B-Cell Lymphoma; Dry Eye Syndrome | Feb 2027 |
| ABBV-859 | – | Phase 1 | Healthy Volunteer | Feb 2027 |
| ABBV-368 | – | Phase 1 | Cancer | Mar 2027 |
| Giloralimab (ABBV-927) Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Advanced Solid Tumors Cancer; Cancer | Mar 2027 |
| ABBV-1451 | – | Phase 1 | Healthy Volunteer | Apr 2027 |
| ABBV-243 | – | Phase 1 | Healthy Volunteers | May 2027 |
| ABBV-7828 | – | Phase 1 | Healthy Subjects | May 2027 |
| ABBV-969 | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer | May 2027 |
| ABBV-453 | – | Phase 1 | Relapsed/Refractory Multiple Myeloma; Chronic Lymphocytic Leukemia | Jul 2027 |
| Azirkitug CD40 agonist monoclonal antibody | CD40 | Phase 1 | Non-Small Cell Lung Cancer | Jul 2027 |
| ABBV-313 | – | Phase 1 | Healthy Volunteers | Feb 2028 |
| ABBV-547 | – | Phase 1 | Healthy Volunteer | May 2028 |
| ABBV-901 Unclear - investigational cancer therapeutic | – | Phase 1 | Ovarian Cancer | Dec 2028 |
| ABBV-519 | – | Phase 1 | Systemic Lupus Erythematosus | Jan 2029 |
| ABBV-711 | – | Phase 1 | Advanced Squamous Tumors | Apr 2029 |
| AGN-193408 SR Prostaglandin analog (implant formulation) | – | Phase 1 | Open-angle Glaucoma | Apr 2029 |
| ABBV-525 | – | Phase 1 | Diffuse Large B-Cell Lymphoma | Jul 2029 |
| ABBV-6628 Monoclonal antibody fragment | – | Phase 1 | Geographic Atrophy | Oct 2029 |
| ABBV-253 | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| ABBV-324 | – | Phase 1 | Hepatocellular Cancer | Sep 2030 |
| ABBV-1758 | – | Phase 1 | Alzheimer's Disease | Oct 2030 |
| Surzetoclax BCL2 family protein inhibitor | BCL2L1 | Phase 1 | Multiple Myeloma | Dec 2030 |
| ABBV-101 | – | Phase 1 | Hematologic Cancer | Mar 2031 |
| ABBV-438 | – | Phase 1 | Multiple Myeloma | Nov 2031 |
| ABBV-2001 T cell engaging bi/tri-specific antibody | – | Phase 1 | Multiple Myeloma | Dec 2035 |
| ABBV-1042 | – | Phase 1 | Healthy Volunteer | – |
| ABBV-637 | – | Phase 1 | Advanced Solid Tumors Cancer; Glioblastoma | – |
| Nacresertib | – | Phase 1 | Healthy Volunteer | – |
| TNB-383B BCMA x CD3 T-cell engaging bispecific antibody | BCMA, CD3E | Phase 1 | Multiple Myeloma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03675308 | Risankizumab | Phase 3 | Psoriatic Arthritis | Immunology | Oct 2020 |
| NCT04305743 | OnabotulinumtoxinA | Phase 4 | Urinary Bladder, Overactive | Genitourinary | Jan 2021 |
| NCT04020510 | OnabotulinumtoxinA | Phase 4 | Overactive Bladder | Genitourinary | Jul 2021 |
| NCT02993523 | Venetoclax | Phase 3 | Acute Myeloid Leukemia (AML) | Oncology | Dec 2021 |
| NCT03064867 | Venetoclax | Phase 1 | Diffuse Large B-cell-lymphoma | Oncology | Aug 2022 |
| NCT04476199 | Venetoclax | Phase 2 | Acute Myeloid Leukemia | Oncology | Feb 2023 |
| NCT05308654 | ABBV-453 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Feb 2024 |
| NCT04763928 | Venetoclax | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2024 |
| NCT05996406 | Venetoclax | Phase 2 | Light Chain (AL) Amyloidosis | Metabolic and endocrine | Nov 2024 |
| NCT06918340 | Lidocaine | Phase 4 | Blood Gas Analysis | Other | Dec 2024 |
| NCT05358639 | Navitoclax | Phase 1 | High Grade Serous Carcinoma | Oncology | Mar 2025 |
| NCT05260125 | Lidocaine | Phase 4 | Hemiplegia | Neurology | Mar 2025 |
| NCT04905810 | Venetoclax | Phase 2 | Acute Myeloid Leukemia | Oncology | May 2025 |
| NCT06310200 | Lidocaine | Phase 1 | Cold Induced Headache | Neurology | May 2025 |
| NCT04817241 | Venetoclax | Phase 1 | Acute Myeloid Leukemia | Oncology | Jun 2025 |
| NCT04572763 | Venetoclax | Phase 1 | Diffuse Large B Cell Lymphoma | Oncology | Jul 2025 |
| NCT06519929 | Lidocaine | Phase 4 | Rib Fractures | Other | Aug 2025 |
| NCT06928376 | Venetoclax | Phase 2 | Acute Myeloid Leukemia | Oncology | Sep 2025 |
| NCT04075981 | OnabotulinumtoxinA | Phase 3 | Cardiac Surgery | Cardiovascular | Oct 2025 |
| NCT05833438 | Venetoclax | Phase 2 | Acute Myeloid Leukemia (AML) | Oncology | Nov 2025 |
| NCT06121466 | Lidocaine | Phase 4 | Anterior Cutaneous Nerve Entrapment Syndrome | Neurology | Dec 2025 |
| NCT06391125 | Lidocaine | Phase 3 | Syphilis Infection | Infectious disease | Dec 2025 |
| NCT07000058 | Lidocaine | Phase 2 | Hand Surgery | Other | Dec 2025 |
| NCT05881265 | Venetoclax | Phase 2 | APL | Oncology | Jan 2026 |
| NCT05870995 | Venetoclax | Phase 2 | Refractory Leukemia | Oncology | Feb 2026 |
| NCT04721015 | ABBV-637 | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Feb 2026 |
| NCT07039877 | Venetoclax | Phase 2 | Acute Lymphobkastic Leukemia | Oncology | Feb 2026 |
| NCT05901974 | Venetoclax | Phase 2 | Acute Leukemia of Ambiguous Lineage | Oncology | Mar 2026 |
| NCT05144243 | Venetoclax | Phase 4 | Acute Myeloid Leukemia (AML) | Oncology | Mar 2026 |
| NCT05144243 | Azacitidine | Phase 4 | Acute Myeloid Leukemia (AML) | Oncology | Mar 2026 |
| NCT05286229 | ABBV-383 (Etentamig) | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Mar 2026 |
| NCT06965933 | Lidocaine | Phase 4 | Regional Anesthesia | Other | Apr 2026 |
| NCT05182385 | Venetoclax | Phase 1 | ALL, Recurrent, Adult | Oncology | Apr 2026 |
| NCT03933735 | TNB-383B | Phase 1 | Multiple Myeloma | Oncology | May 2026 |
| NCT06979141 | Lidocaine | Phase 3 | Cough | Other | Jun 2026 |
| NCT03539536 | Telisotuzumab Vedotin (ABBV-399) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Jul 2026 |
| NCT02099058 | Telisotuzumab Vedotin (ABBV-399) | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Aug 2026 |
| NCT07032597 | Lidocaine | Phase 3 | Mid Face Volume Deficit | Other | Sep 2026 |
| NCT06953934 | ABBV-932 | Phase 1 | Healthy Volunteer | Other | Sep 2026 |
| NCT02988960 | Budigalimab (ABBV-181) | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Sep 2026 |
| NCT02988960 | Giloralimab (ABBV-927) | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Sep 2026 |
| NCT06487559 | Budigalimab (ABBV-181) | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Sep 2026 |
| NCT06487559 | Livmoniplimab | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Sep 2026 |
| NCT07222709 | ABBV-1042 | Phase 1 | Healthy Volunteer | Other | Sep 2026 |
| NCT05566054 | Venetoclax | Phase 2 | Acute Monocytic Leukemia | Oncology | Sep 2026 |
| NCT07008846 | Upadacitinib | Phase 3 | Moderate to Severe Rheumatoid Arthritis | Immunology | Sep 2026 |
| NCT05657639 | Venetoclax | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2026 |
| NCT07649954 | Nacresertib | Phase 1 | Healthy Volunteer | Other | Oct 2026 |
| NCT07730554 | Trenibotulinumtoxine (AGN-151586) | Phase 2 | Forehead Lines | Other | Oct 2026 |
| NCT07680686 | Ubrogepant | Phase 1 | Healthy Volunteer | Other | Oct 2026 |
| NCT05336812 | Venetoclax | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Oct 2026 |
| NCT07661758 | Lidocaine | Phase 3 | Intravenous Lidocaine | Other | Nov 2026 |
| NCT05822752 | Budigalimab (ABBV-181) | Phase 2 | Hepatocellular Carcinoma | Oncology | Nov 2026 |
| NCT04895436 | Venetoclax | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | Oncology | Nov 2026 |
| NCT03980171 | Venetoclax | Phase 1 | Follicular Lymphoma | Oncology | Nov 2026 |
| NCT05226455 | Venetoclax | Phase 1 | MDS | Oncology | Nov 2026 |
| NCT05053659 | Venetoclax | Phase 1 | Relapsed Non Hodgkin Lymphoma | Oncology | Nov 2026 |
| NCT05822752 | Livmoniplimab | Phase 2 | Hepatocellular Carcinoma | Oncology | Nov 2026 |
| NCT06389136 | Upadacitinib | Phase 3 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT06389136 | Upadacitinib | Phase 3 | Atopic Dermatitis | Immunology | Nov 2026 |
The 60 nearest readouts of 582 trials; the rest in the app.
Cash of $10.8bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.